Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company is also developing ALG-020572, an antisense oligonucleotide to decrease HBsAg levels; and ALG-055009, a small molecule THR-Ã agonist for the treatment of non-alcoholic steatohepatitis. In addition, it is developing siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. The company has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting SARS-CoV-2; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
IPO Year: 2020
Exchange: NASDAQ
Website: aligos.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/19/2024 | $75.00 | Buy | H.C. Wainwright |
| 1/6/2023 | $2.00 → $3.00 | Neutral → Overweight | Piper Sandler |
| 1/6/2023 | $2.50 → $3.00 | Hold → Buy | Jefferies |
| 3/23/2022 | $15.00 → $4.00 | Overweight → Neutral | Piper Sandler |
| 3/11/2022 | $47.00 → $15.00 | Overweight | Piper Sandler |
| 3/11/2022 | $10.00 → $11.00 | Outperform | SVB Leerink |
| 2/16/2022 | $15.00 → $10.00 | Outperform | SVB Leerink |
| 1/7/2022 | $30.00 → $12.00 | Overweight → Neutral | JP Morgan |
| 1/7/2022 | $29.00 → $15.00 | Outperform | SVB Leerink |
| 1/6/2022 | Buy → Hold | Jefferies |
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 2:00pm ET. A live webcast of the presentation will be accessible by visiting the Presentation & Events section on the "Investors" page of Aligos' website at www.aligos.com. A replay of the webcast will be available following the presentation for at least 30 days. About Aligos Aligos Therapeutics, Inc. (NASDAQ:ALGS) is
SOUTH SAN FRANCISCO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Laura Kavanaugh, JD as Vice President, Head of Legal, effective immediately. "I am thrilled to welcome Laura to the Aligos team," said Lesley Ann Calhoun, Executive Vice President, Chief Operating Officer, and Chief Financial Officer at Aligos. "Laura brings with her a wealth of experience in all legal aspects from both biotech companies as well as large pharmaceutical firms. Her extensive knowledge and broad expe
SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos", "Company")), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase an aggregate of 26,000 shares of the Company's stock (the "Inducement Grant") to a newly hired employee on May 13, 2025 (the "Grant Date"), in connection with the commencement of employment. The Inducement Grant was granted pursuant to Aligos' 2024 Inducement Plan (the "Plan") as an inducement m
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from eight presentations at the European Association for the Study of the Liver (EASL) Congress 2025, being held May 7 – 10, 2025 in Amsterdam, Netherlands. "We are pleased to have eight presentations at this year's EASL Congress from programs across our pipeline," stated Lawrence Blatt, PhD, MBA, Chairman, President, & CEO of Aligos Therapeutics. "In particular, we are excited to share an update on the 96-week data f
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the first quarter 2025. "We continued to make progress towards our corporate development plans aimed at advancing life-saving therapies for viral and liver diseases," stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. "Over the past few months, we raised over $100M to begin our important Phase 2 study of ALG-000184 i
SOUTH SAN FRANCISCO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company's first quarter 2025 financial results on Tuesday, May 6, 2025, before the open of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. (NASDAQ:ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D
SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced eight abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2025, being held May 7 – 10, 2025 in Amsterdam, Netherlands. The abstracts released today can be found on the EASL website at https://www.easlcongress.eu/. Details on the abstracts are as follows: ALG-000184: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (H
SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from three oral presentations at the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL) 2025, being held March 26 - 30, 2025 in Beijing, China. "We are pleased to present preliminary data out to 96 weeks in our Phase 1 study of ALG-000184, which continues to demonstrate first-/best-in-class reductions in important HBV markers," stated Lawrence Blatt, PhD, MBA, Chairma
SOUTH SAN FRANCISCO, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos", "Company")), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option to purchase an aggregate of 4,000 shares of the Company's stock (the "Inducement Grant") to a newly hired employee on March 11, 2025 (the "Grant Date"), in connection with the commencement of employment. The Inducement Grant was granted pursuant to Aligos' 2024 Inducement Plan (the "Plan") as an inducemen
SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the fourth quarter and full year 2024. "2024 was a pivotal year for the company, paving the way for the future of Aligos," stated Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer of Aligos Therapeutics. "That future looks bright as we move ALG-000184 closer towards a Phase 2 clinical study, which is expected to begin in mid-2025. We continue to b
4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)
4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)
4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)
4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)
3 - Aligos Therapeutics, Inc. (0001799448) (Issuer)
4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)
4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)
4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)
4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)
4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)
SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)
SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)
SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)
SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)
SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)
SC 13G - Aligos Therapeutics, Inc. (0001799448) (Subject)
SC 13G - Aligos Therapeutics, Inc. (0001799448) (Subject)
SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)
SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)
SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)
ALG-055009 dose groups met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured by MRI-PDFFPlacebo-adjusted median relative reductions in liver fat were up to 46.2% with a clear dose responseALG-055009 was well-tolerated with no serious adverse events or dose reductions. Importantly, ALG-055009 dose groups had a similar incidence of gastrointestinal-related adverse events with less diarrhea compared to placeboSignificant reductions in atherogenic lipids, including LDL-C, lipoprotein (a), and apolipoprotein B were observedConference call scheduled for 8:30am ET/5:30am PT today SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Alig
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos", "Company"))), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Company will share the topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, in metabolic-dysfunction associated steatohepatitis (MASH) subjects on Thursday, September 19, 2024 prior to the market open. Following the announcement, the Company will host a conference call and webcast at 8:30am ET/5:30am PT. Conference Call & Webcast Details Th
CAM (ALG-000184) continues to demonstrate best in class potential in Phase 1bASO (ALG-020572) completed dosing in Phase 1a (HVs); Phase 1b study (CHB) initiated – 1st cohort fully enrolledsiRNA (ALG-125755) progressing on track through Phase 1 enabling nonclinical studiesTHR-β (ALG-055009) currently dosing in healthy volunteers and subjects with hyperlipidemiaMultiple COVID-19 3CL protease inhibitor drug candidates without need for ritonavir boosting identified – all more potent than nirmatrelvirMerck expanded the NASH research collaboration utilizing Aligos' proprietary oligonucleotide technology Cash, cash equivalents and investments of $205.8 million as of December 31, 2021 A sufficient
SOUTH SAN FRANCISCO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Laura Kavanaugh, JD as Vice President, Head of Legal, effective immediately. "I am thrilled to welcome Laura to the Aligos team," said Lesley Ann Calhoun, Executive Vice President, Chief Operating Officer, and Chief Financial Officer at Aligos. "Laura brings with her a wealth of experience in all legal aspects from both biotech companies as well as large pharmaceutical firms. Her extensive knowledge and broad expe
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of David Perry as Vice President of Business Development, effective immediately. "We are pleased to welcome David to the Aligos team during this exciting time for the company," said Lesley Ann Calhoun, Executive Vice President and Chief Financial Officer at Aligos. "David's expertise in leading valuable partnerships will be instrumental as we strategically look to maximize the potential of our best-in-class pipeline
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos", the "Company"))), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced the appointment of Heather Preston, M.D. and Margarita Chavez, J.D. as Class II Independent Directors to the Board of Directors, effective August 7, 2024. Dr. Preston will join the Nominating and Corporate Governance Committee as Chair and Ms. Chavez will join the Audit Committee. "We are pleased to announce the appointment of Dr. Heather Preston and Margarita Chavez to our Board of Directors," stated
Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company's Board of Directors effective May 23, 2024. "We are pleased to welcome Dr. Martell to the Delcath Board," said John Sylvester, Chairman of the Delcath Board of Directors. "Dr. Martell's extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving pa
Jordyn Tarazi joins as Vice President, Investor Relations and Corporate Communications Nikhil Aneja, CPA, CA appointed as Vice President, Finance SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) ("Aligos"), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced the appointments of Jordyn Tarazi as Vice President, Investor Relations and Corporate Communications and Nikhil Aneja as Vice President, Finance, effective immediately. "We are delighted to welcome Jordyn and Nikhil to the team," said Lesley Ann Calhoun, Executive Vice Presi
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has appointed Bridget Martell, MA, M.D., to the Company's board of directors. "We are pleased to welcome Dr. Martell to our board of directors. Her decades of experience in therapeutics development and leadership in biotechnology will be invaluable to the company as we continue to move our therapeutic candidates, including those for chronic hepatitis B and NASH, through the clinic," said Lawrence Blatt, Ph.D., MB
SOUTH SAN FRANCISCO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has appointed James Scopa, J.D., MBA, to the Company's board of directors. "We are thrilled to add someone of Jim's experience and accomplishments to Aligos' board, as the company continues its arc from its earliest, private, preclinical phase to growing into its role as an established clinical-stage public biopharma company," said Aligos Chief Executive Officer Lawrence Blatt, Ph.D., MBA. "Aligos will look to J
H.C. Wainwright initiated coverage of Aligos Therapeutics with a rating of Buy and set a new price target of $75.00
Piper Sandler upgraded Aligos Therapeutics from Neutral to Overweight and set a new price target of $3.00 from $2.00 previously
Jefferies upgraded Aligos Therapeutics from Hold to Buy and set a new price target of $3.00 from $2.50 previously
Piper Sandler downgraded Aligos Therapeutics from Overweight to Neutral and set a new price target of $4.00 from $15.00 previously
Piper Sandler reiterated coverage of Aligos Therapeutics with a rating of Overweight and set a new price target of $15.00 from $47.00 previously
SVB Leerink reiterated coverage of Aligos Therapeutics with a rating of Outperform and set a new price target of $11.00 from $10.00 previously
SVB Leerink reiterated coverage of Aligos Therapeutics with a rating of Outperform and set a new price target of $10.00 from $15.00 previously
JP Morgan downgraded Aligos Therapeutics from Overweight to Neutral and set a new price target of $12.00 from $30.00 previously
SVB Leerink reiterated coverage of Aligos Therapeutics with a rating of Outperform and set a new price target of $15.00 from $29.00 previously
Jefferies downgraded Aligos Therapeutics from Buy to Hold
SCHEDULE 13G - Aligos Therapeutics, Inc. (0001799448) (Subject)
SCHEDULE 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)
SCHEDULE 13G - Aligos Therapeutics, Inc. (0001799448) (Subject)
10-Q - Aligos Therapeutics, Inc. (0001799448) (Filer)
8-K - Aligos Therapeutics, Inc. (0001799448) (Filer)
DEFA14A - Aligos Therapeutics, Inc. (0001799448) (Filer)
DEF 14A - Aligos Therapeutics, Inc. (0001799448) (Filer)
PRE 14A - Aligos Therapeutics, Inc. (0001799448) (Filer)
EFFECT - Aligos Therapeutics, Inc. (0001799448) (Filer)
424B3 - Aligos Therapeutics, Inc. (0001799448) (Filer)